RxDoctor Payments Data

Laura Fernandes, MD

Interventional Cardiology · Shenandoah, TXNPI 1811083116

Payments from drug & device makers

$13,127in general payments, 2019–2025

Across 547 payments — averaging $24.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Amgen$1K
  • Novartis$1K
  • Medtronic$1K
  • Merck$908
  • Johnson & Johnson$814
  • plus $5K from 36 others

What the payments were for

  • Travel & lodging$1,32710%
  • Food & beverage$11,57488%
  • Education$2262%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,127 in reported general payments places this provider in the 55th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$642,455
Medicare patients
796
Services billed
6,407

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab188$163,313
XareltoRivaroxaban118$91,896
EliquisApixaban108$89,943
EntrestoSacubitril/Valsartan57$89,125
OzempicSemaglutide43$45,109
Praluent PenAlirocumab18$15,546
Ranolazine ErRanolazine143$14,443
FarxigaDapagliflozin Propanediol14$13,145
Repatha SyringeEvolocumab15$9,219
EdarbiAzilsartan Medoxomil14$9,143
Valsartan116$4,167
Rosuvastatin Calcium233$3,907
Varenicline Tartrate16$2,990
Losartan Potassium254$2,795
Metoprolol Succinate172$2,591

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$814$91,896118 claims
PfizerEliquis$264$89,943108 claims
NovartisEntresto$1,318$89,12557 claims
Novo NordiskOzempic$156$45,10943 claims
AstraZenecaFarxiga$152$13,14514 claims
Arbor Pharmaceuticals, Inc.Edarbi$351$9,14314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Shenandoah

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →